论文部分内容阅读
正常育龄妇女的子宫液的纤溶活性有周期变化:增殖期增强,周期中期活性最大,黄体期逐渐降低,行经前又增强。子宫液中纤溶活性与着床有密切关系。作者对口服避孕药(OC)使用者的子宫液的纤溶活性进行了研究。包括二组有规则行经(每4周一次)的健康妇女,其所用的OC中含乙炔雌二醇50μg加D—18甲基炔诺酮250μg或3—去氧炔诺酮2.5mg。Ⅰ组40名妇女服OC至少6个月,每例于月经周期不同时间随机取子宫液一次。Ⅱ组9名妇女在用OC前及服OC期间各取2次子宫液(共4次),一次在月经的前半周期(第6～14天),另一次在月经的后半期(第15～28天)。采取方法是在无菌操作下将连有注射器的儿科鼻饲管(外径3mm,内径2mm)插入宫腔,用较低负压抽吸取少
Fibrinolytic activity of uterine fluid in normal women of childbearing age has periodic changes: the proliferative phase is enhanced, the mid-cycle activity is the largest, the luteal phase is gradually decreased, and the pre-menstrual cycle is enhanced. Uterine fluid fibrinolytic activity and implantation are closely related. The authors investigated the fibrinolytic activity of uterine fluid in oral contraceptives (OC) users. Two groups of healthy women with regular (once every 4 weeks) routes of OC were included with 50 μg of ethinyl estradiol plus 250 μg of D-18 norethindrone or 2.5 mg of 3-noroxorene. Forty women in group I received OC for at least 6 months, each with uterine fluid taken randomly at different times of the menstrual cycle. In group Ⅱ, 9 women took 2 times of uterine fluid (4 times) before OC and before taking OC, one in the first half of menstrual cycle (days 6-14) and the other in second half of menstrual cycle (15th ~ 28 days). The method is to be under sterile operation will be connected with a syringe pediatric nasal feeding tube (diameter 3mm, diameter 2mm) into the uterine cavity, with less suction to take less